Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Apr 15, 2004; 10(8): 1146-1151
Published online Apr 15, 2004. doi: 10.3748/wjg.v10.i8.1146

Full Size Figure Download Figure

Figure 1 Dynamic analysis of CIK cellular phenotypes by flow cytometry.

Citation: Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10(8): 1146-1151
URL: https://www.wjgnet.com/1007-9327/full/v10/i8/1146.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i8.1146

Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10(8): 1146-1151 [PMID: 15069715 DOI: 10.3748/wjg.v10.i8.1146]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.